Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07668180
PHASE2

A Study to Evaluate the Efficacy and Safety of IN-207907 Injection in Elderly Patients With Sarcopenia

Sponsor: HK inno.N Corporation

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn if intervention can treat sarcopenia in the elderly. Researchers will compare IN-207907 120 mg, 240 mg, 360 mg and placebo to see if SPPB score improves.

Official title: A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of IN-207907 Injection in Elderly Patients With Sarcopenia

Key Details

Gender

All

Age Range

65 Years - Any

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2026-09

Completion Date

2028-02

Last Updated

2026-06-25

Healthy Volunteers

No

Interventions

DRUG

IN-207907 120 mg

IN-207907 120 mg will be administered by intravenous injection at 4-week intervals for a total of 3 doses.

DRUG

IN-207907 240 mg

IN-207907 240 mg will be administered by intravenous injection at 4-week intervals for a total of 3 doses.

DRUG

IN-207907 360 mg

IN-207907 360 mg will be administered by intravenous injection at 4-week intervals for a total of 3 doses.

DRUG

Placebo

Placebo will be administered by intravenous injection at 4-week intervals for a total of 3 doses.